Management of DE With IPL in Combination With DQS

• Status: Not yet recruiting
• Trial end date: 2023-07-01
• Target enrollment: 0
• Participant gender: All

Summary

Intense pulsed light (IPL) has been reported to improve signs and symptoms of dry eye (DE). Additionally, meibomian gland secretion of lipids has been observed to improve through the use of IPL. Diquafosol ophthalmic solution (DQS) stimulates P2Y2 receptors on the ocular surface, which enhances mucin secretion from goblet cells. Therefore, tear film stability and hydration of the ocular surface can be achieved independent from lacrimal glands function. The purpose of this prospective study was to evaluate and compare the effects of IPL (IPL group), DQS (DQS group) and IPL in combination with DQS (IPL+ group) in participants with persistent DE. Tear film lipid layer (TFLL), non-invasive breakup time (NITBUT), tear meniscus height (TMH), corneoconjunctival staining score (CS), meibum gland (MG) function, conjunctival hyperemia (RS score), ocular surface disease index (OSDI) will be assessed and compared at baseline, day-14, and day-28.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: He Eye Hospital

Criteria

Inclusion Criteria:

• Age ≥18 years

• The presence of at most one symptom including burning, foreign body sensation, itching or eye fatigue for 3 months

• OSDI score ≥ 13 and TBUT <5 s or NIBUT < 10s

• Able and willing to comply with the treatment/follow-up schedule

Exclusion Criteria:

• A recent history (past 30 days) of topical ophthalmic medication use, including antibiotics, steroids, non-steroidal anti-inflammatory drugs, or required the chronic use of topical ophthalmic medications

• Eyelids or intraocular tumors that should not put pressure

• Active allergy or infection or inflammatory disease that may have prevented the subjects from completing the study at the ocular surface

• Any structural change in lacrimal passage

• Glaucoma

• Diabetes or other systemic, dermatologic, or neurologic diseases that affect the health of ocular surface

• Use of any systemic anti-inflammatory drugs or medication that may interfere with tear production, such as antianxiety, antidepressive, and antihistamine medications within 3 months